4//SEC Filing
PYSZCZYMUKA GREG 4
Accession 0001193125-25-322646
CIK 0001403708other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:00 PM ET
Size
8.7 KB
Accession
0001193125-25-322646
Insider Transaction Report
Form 4
Evoke Pharma IncEVOK
PYSZCZYMUKA GREG
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-12-17−5,833→ 0 totalExercise: $5.26→ Common Stock (5,833 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-12-17−1,155→ 0 totalExercise: $3.45→ Common Stock (1,155 underlying)
Footnotes (2)
- [F1]In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the "Merger Agreement"), by and among the Issuer, QOL Medical, LLC ("Parent") and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
- [F2]Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Company Option") outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
Documents
Issuer
Evoke Pharma Inc
CIK 0001403708
Entity typeother
Related Parties
1- filerCIK 0001952920
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 4:00 PM ET
- Size
- 8.7 KB